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Striatal dopaminea b s t r a c t
Cerium oxide nanoparticles (CeO2NPs) is an efficient neuroprotective agent and showed promising effects
in some neurodegenerative diseases such as Alzheimer’s disease and multiple sclerosis. However, the
implication of CeO2NPs in Parkinsonism remains to be investigated.
The aim of this study was to assess the possible role of CeO2NPs as a neuroprotective agent against the
development of behavioral and biochemical changes in rat model of Parkinson’s disease. Thirty rats were
included and received left intrastriatal injection of either saline (controls, n = 10) or 6-hydroxy dopamine
(6-OHDA) in untreated group (n = 10) and 10 rats were received intraperitoneal injection of low dose
CeO2NPs two hours before surgery, and continued once daily for 6 weeks (preventive group). At the
end of experimental period, rats were subjected to behavioral assessment and then killed for biochemical
analysis of striatal dopamine levels, oxidative stress markers and caspase-3 activity. Results showed that
CeO2NPs resulted in partial neuroprotection against disturbances in motor performance. It also partially
decreased apoptosis and oxidative stress in preventive group, while it failed to increase striatal dopamine
level as compared to untreated rats. The present study verified some neuroprotective effects of CeO2NPs
in 6-OHDA-induced Parkinsonian rats through their antioxidant and anti apoptotic effects. Some of these
effects persisted till the end of six weeks whereas others declined after three weeks. A larger dose may be
needed to produce more valuable effects and to maintain protection for a longer period.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Parkinson’s disease (PD) is currently regarded as the most com-
mon degenerative disorder of the aging brain after the Alzheimer’s
disease with extremely high psychosocial impacts and noticeabledeclines in patients’ quality of life.1 The cardinal biochemical
abnormality in PD is the profound deficit in brain dopamine level
attributed to the loss of neurons of the nigrostriatal dopaminergic
pathway. The exact pathogenic mechanism for neurodegeneration
observed in PD is not fully understood. However, The concept that
free radical–mediated neuronal injury has been suggested as the
main hypothesis for PD pathogenesis.2,3 Multiple genetic and envi-
ronmental risk factors interfere with mitochondrial function,
increase free radicals production with eventual release of
apoptosis-initiating factors.4–8
6-Hydroxydopamine (6-OHDA), a hydroxylated analog of dopa-
mine, was found to induce degeneration of dopaminergic neurons
and results in rat model of Parkinsonism.9 Intracellular uptake of
6-OHDA is mediated by dopamine or noradrenaline membrane
transporters (DAT and NAT respectively) due to its structural
similarity with endogenous catecholamines.10 Once taken up into
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oxidized leading to the generation of reactive oxygen species and
ultimately, oxidative stress-related cytotoxicity.11
Recently, nanotechnology has become a main focus of biomed-
ical research.12 In particular, cerium oxide nanoparticles (CeO2NPs)
have distinctive properties that can be effective in nanotherapeu-
tics. The small size of these nanoparticles gives them a high surface
area to volume ratio, in addition to the ability of cerium to exist in
either a +3 (reduced) or +4 (oxidized) state at the particle surface:
Ce3+are associated with oxygen vacancies. Therefore, CeO2NPs can
be used as a scavenger of superoxide anions.13,14 Moreover,
CeO2NPs were shown to exhibit superoxide dismutase (SOD) and
catalase enzymes mimetic activities in a redox-state dependent
manner.14
CeO2NPs were effective to prevent macular degeneration15 and
the formation of neovascular lesions in the retina,16 to decrease
hepatic oxidative stress linked to the progression of diabetes17
and to promote wound-healing activity.18 Additionally, CeO2NPs
were proven to be extremely protective for cardiac19 and neuronal
cells.20 The use of CeO2NPs in the prevention of neurodegenerative
diseases in which oxidative stress plays a major role in its pathol-
ogy may hold promising prophylactic potential. However, the
application of CeO2NPs in PD remains to be investigated.
The aim of the present work was to assess the possible effects of
cerium oxide nanoparticles (CeO2NPs) in prevention of motor,
behavioral and neurochemical changes in rat model of Parkinson’s
disease.2. Materials and methods
2.1. Experimental animals
30 Adult male Wistar rats weighing 200–220 g were used (pro-
cured from Experimental Animal house in Physiology Department,
Alexandria University). Animals were maintained at room temper-
ature under standard conditions of a 12-h light-dark cycle with
food and water ad libitum. They were allowed to acclimatize for
1 week prior to experimentation. All experiments were carried
out during the light phase between 9:00 and 15:00. Procedures
involving animals and their care were conducted in conformity
with ethical guide-lines of Alexandria University on laboratory ani-
mals and the protocol was approved by the Faculty of Medicine,
Alexandria University Ethics Committee.
The animals were divided into the following groups:
2.1.1. Control (sham-operated) group
This group included 10 rats received a single left intrastriatal
(IS) stereotaxic injection of 2 ll of vehicle (0.9% saline with 0.1%
ascorbic acid, pH 5.5) followed after 3 weeks by daily intraperi-
toneal (i.p) injection of 0.5 ml phosphate buffered saline (PBS) for
another 3 weeks.
2.1.2. 6-OHDA- untreated group
It included 10 rats received a single dose of left intrastriatal
injection of 10 lg of 6-hydroxydopamine hydrobromide (6-
OHDA- HBr) (Sigma-Aldrich) dissolved in 2 ll of the same vehicle
to induce PD model. Ascorbic acid was used to stabilize 6-OHDA-
HBr, as it prevents oxidation of 6-OHDA-HBr to an inactive form.
After 3 weeks, these rats were injected with 0.5 ml PBS i.p daily
for 3 weeks.21
2.1.3. Cerium oxide nanoparticles (CeO2NPs)- preventive group
10 rats were injected stereotaxically with 10 lg of 6-OHDA-
HBr dissolved in 2 ll of vehicle into the left striatum for 3 weeks.
Rats were received i.p injection of low dose CeO2NPs (0.1 mg/kg)in 0.5 ml PBS two hours before surgery, and continued once daily
for 6 weeks.22
2.2. Experimental procedure
The rats were anaesthetized (by ketamine 100 mg/kg and xyla-
zine 5 mg/kg, i.p.) and fixed in a stereotaxic frame (David kopf
instrument) with the incisor bar set at 3.3 mm, to adjust head
level.
The scalp was incised and the skull was exposed. A small burr
hole was made in the skull by dental drill above the left striatum
1 mm anterior to bregma and 2.6 mm left of midline. The dura
was cut and a 26 gauge blunt-tipped needle attached with 5 lL
Hamilton syringe was slowly lowered to a depth of 5.0 mm below
the surface of the skull (bregma) according to the Atlas of Paxinos
and Watson21,23.
Rats were subjected to unilateral (left) intrastriatal injection
with either of 2 ll vehicle (in the control group) or 10 lg of 6-
OHDA- HBr dissolved in vehicle (in 6–OHDA- injected group) was
slowly injected at a rate of 0.4 ll/min. The needle was left in place
for an additional 5 min following the injection and then slowly
withdrawn to prevent the reflux of the drug. The burr holes were
filled with Gelfoam and the incision was closed with sutures.21
The animals were placed individually in a heated recovery
chamber until they recovered from anesthesia. Then rats were
housed together in a group of four animals per cage. Food and
water was kept inside the cages for the first week so that animals
could easily access it without any physical trauma. After surgery,
all rats received gentamicin (5 mg/kg, i.p) for 3 days to prevent
sepsis, and meloxicam (1 mg/kg, i.p.) for analgesia. Rats were also
given daily injection of saline (500 ll, s.c.), to prevent dehydration
until they regained their pre-surgery weight.21
2.2.1. Behavioral tests
All rats included in this study were subjected to behavioral tests
2–3 weeks after surgery to confirm the manifestations of Parkin-
sonism and development of PD in rat modes and to compare
between untreated and preventive group. The tests were once
more performed at the end of experimental period (at the end of
6 weeks) to assess the preventive role of cerium oxide nanoparti-
cles against behavioral and motor changes that accompany PD.
Behavioral tests include the followings:
1. Open field test.24
2. Rotarod test.25
3. Stepping test and initiation time.26
2.2.2. Striatal tissue neurobiochemical assays
On the last experimental day, the rats were sacrificed by decap-
itation immediately after behavioral assessments. The whole brain
was removed and washed with ice cold saline and the left striatum
was dissected as previously described.27 For dopamine estimation,
the striatum (20% w/v) was homogenized and deproteinized in
0.2 M perchloric acid containing 100 lM EDTA2Na. The homoge-
nate was left for 30 min. to deproteinize. Then, the homogenate
was centrifuged at 10,000g for 15 min at 0 C (Hettich Universal
320R refrigerated centrifuge). After centrifugation, the supernatant
was adjusted to pH = 3.35 by adding 1 M acetic acid, and then fil-
tered through 0.45-lm membrane filter (Millipore, Bedford, MA,
USA). For oxidative stress parameters assays, part of striatum
was homogenized in 10 times (w/v) ice cold 0.1 M phosphate buf-
fer (pH 7.4) and centrifuged at 10,000g for 15 min at 4 C.For cas-
pase 3 activity assay, another part of the specimen was
homogenized with caspase 3 reaction buffer. Aliquots of brain
homogenate supernatant were analyzed in duplicate for total
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reagent with bovine serum albumin as a standard.28
2.2.2.1. Dopamine high performance liquid chromatography (HPLC)
assay. For dopamine HPLC assay, Arsene et al. method was adopted
with slight modifications. Briefly, 20 ll of the filtered striatal
supernatant was injected into an HPLC reversed–phase system
(Agilent Technologies) with a Zorbax SB-C18 250  4.6 mm col-
umn (Agilent Technologies). The mobile phase consisted of
0.8 mM EDTA-Na2, 0.12 M NaH2PO4H2O, 0.646 g sodium heptane
sulphonate and 60% methanol. Dopamine was detected using an
UV detector (210 nm). HPLC results were read off dopamine cali-
bration curve and were normalized to total tissue proteins to be
expressed as ng/mg protein.29,30
2.2.2.2. Oxidative stress assay. Total antioxidant capacity (TAC), the
lipid peroxidation marker, malondialdehyde (MDA) and nitrite
were determined in striatal tissue supernatant by colorimetric
technique using commercial kits (Biodiagnostic, Egypt), according
to the manufacturer’s protocol. The results of TAC were normalized
to total tissue proteins to be expressed as mmol/mg protein,31
whereas the results of MDA were normalized to tissue weight to
be expressed as ng/gm tissue.32 The results of nitrite were normal-
ized to total tissue proteins to be expressed as lmol/mg protein.33
2.2.2.3. Caspase-3 activity assay. As a marker for apoptosis in stri-
atal tissue, caspase-3 enzymatic activity was measured by colori-
metric reaction provided by R&D Systems. Caspase-3 activity was
expressed as the ratio to the control levels and its results were nor-
malized to total tissue proteins.34
2.3. Statistical analysis
Statistical analysis was performed using Statistical Package for
Social Sciences 20.0 for Windows (SPSS, Chicago, IL). The distribu-
tions of quantitative variables were tested for normality using
Shapiro-Wilk’s test. If revealed normal distribution, data were
described as mean ± S.E.M. and analyzed by one way ANOVA fol-
lowed, when significant, with Post Hoc Tukey test. For abnormally
distributed data, Kruskal Wallis test was used to compare between
different groups and pair wise comparison was assessed using
Mann-Whitney test. Wilcoxon signed ranks test was used to com-
pare performance of the diseased limb versus the opposite one in
the same group in the stepping test. Significance of the obtained
results was judged at the 5% level.
3. Results
3.1. Behavioral findings: (Tables 1–3)
3.1.1. Open field test
Intrastriatal injection of 6-OHDA in the untreated group
resulted in a significant impairment in locomotor and exploratory
behavior as seen after three weeks by decreased number of crossed
squares and number of rears and increased latency to start moving
and rearing versus the control group. This impairment was persis-
tent after six weeks giving the same significant difference from
control group and no significant difference was detected in com-
paring the results of open field test in untreated group after three
and six weeks.
Treatment of rats with low dose of (CeO2NPs) in the preventive
group succeeded in preventing the development of impairment in
locomotor behavior after three weeks as determined by significant
decrease in latency to move and rear with a significant increase in
number of crossed squares and number of rears as compared tountreated group, although, this dose failed to return these tests
back to normal, where a significant change was still detected in
comparison to control group except for latency to rear where no
significant difference was noticed.
After six weeks, the low dose of (CeO2NPs) was not effective in
improving open field test as noticed after three weeks. As regard
latency to rear, a significant increase was detected in preventive
group after six weeks when compared to results after three weeks.
In addition, number of rears decreased as compared to number of
rears after three weeks and no significant difference was detected
between preventive and untreated group. On the other hand, the
low dose of (CeO2NPs) in the preventive group was able to main-
tain the improvement in latency to move and number of crossed
squares as observed after three weeks and no significant difference
was detected after six weeks when compared to results after three
weeks.
3.1.2. Rotarod test
A significant decrease in the mean of latency to fall time was
reported in 6-OHDA group after three weeks as compared to con-
trol group which persisted also after six weeks. This reduction
was in part prevented by low dose administration of CeO2NPs in
the preventive group as a significant increase was detected in this
group after three and six weeks when compared to untreated
group but still significantly lower than control group. However,
the results of treatment of rats with (CeO2NPs) were less effective
after six weeks than after three weeks as significant difference was
detected in comparing rotarod test results after three and six
weeks in the preventive group.
3.1.3. Stepping test and initiation time
The motor performance of right forepaw (contralateral to injec-
tion site) of 6-OHDA untreated group was significantly impaired
after three and six weeks when compared to either the left paw
of the same group or right paw of the control group. The number
of steps taken by right forelimb of 6-OHDA group was significantly
less as well as the mean time to initiate steps by this limb was sub-
stantially delayed compared to left forelimb of the 6 OHDA group
and to the right forelimb of control group. In control group, there
was no significantly difference in motor performance of both fore-
limbs. Early injection of low dose of CeO2NPs in preventive group
resulted in partial protection against this motor performance
impairment of right forelimb after three and six weeks as the num-
ber of steps taken by right forelimb were significantly increased
and the mean time to initiate steps by this limb was significantly
decreased in comparison to untreated group but they did not
return back to control values. There was no significant difference
in stepping test and initiation time in both untreated and preven-
tive group in comparing results after three and six weeks, except
for the time taken to initiate steps by right forelimb in preventive
group which was significantly increased after six weeks as com-
pared to that after three weeks but it was still significantly lower
than untreated group (see Fig. 1).
3.2. Neurobiochemical markers
3.2.1. Striatal dopamine level (Fig. 2)
There was a significant decrease in striatal dopamine level in 6-
OHDA untreated group versus control rats. Meanwhile, low pre-
ventive dose of CeO2NPs were not able to keep high dopamine
levels as controls and dopamine levels were not significantly dif-
ferent from those of untreated 6 OHDA rats.
3.2.2. Oxidative stress markers (TAC, MDA and nitrite) (Figs. 3–5)
The present study revealed a significant increase in striatal MDA
and nitrite levels and decrease in striatal TAC level in 6-OHDA
Table 1
Neuro-behavior finding in control, 6-OHDA untreated and preventive groups 3 weeks after intrasrtiatal injection of 6-OHDA.
Controls 6-OHDA CeO2NPs –preventive group KWv2 P
Open field parameters
Latency to move in (seconds) 4 (3–6.5) 84 (70–95)$$ 31.5(23–40.5)$$,## 38.587 <0.001
Number of crossed squares 25 (19.3–29) 9 (6–10)$$ 17.5(12.8–20.5)$,## 34.398 <0.001
Latency to rear (seconds) 10 (7.8–16.5) 19.5 (12–43)$ 11.5 (10–17.3)# 8.898 0.012
Number of rears 13.5 (8–15) 5 (3–7.8)$$ 8 (5.8–8.8)$,# 19.898 <0.001
Rotarod test F P
Mean time of latency to falla 93.7 ± 17.2 32.4 ± 5.94$$ 52.9 ± 5.92$$,## 199.900 <0.001
Stepping test KWv2 P
Total Steps taken by Rt forelimbb 20.5 (18.8–23.5) 3.0(1.3–5)$$ 7.0(5.8–9.3)$$,## 35.848 <0.001
Total Steps taken by Lt forelimbb 21.5 (19.8–22.8) 22.0(19–24)** 19.5 (15–22)* 3.621 0.164
Time to initiate steps by Rt forelimba 4.0(3.4–5.1) 29.6(25.1–35)$$ 16.1(15.3–18.5)$$,## 39.399 <0.001
Time to initiate steps by Lt forelimba 4.67 (3.2–6.2) 5.50 (4.3–6.6)** 6.67 (5.2–7.7)* 4.354 0.113
Data were expressed as medians (inter-quartile range) and analyzed by non–parametric ANOVA (Kruskal Wallis), followed when significant by MannWhitney test, except for
mean time of latency to fall in rotarod test, where data were expressed as Mean ± SD and analyzed by (one way ANOVA), followed by Post-Hoc Tukey test. Each group
contained 10 rats.
a Data represented mean of three trials for each rat.
b Data were expressed as the sum of forehand and backhand steps made by each forepaw.
$ P 6 0.05.
$$ P 6 0.001versus control group.
# P 6 0.05.
## P 6 0.001 versus 6-OHDAgroup. Wilcoxon signed ranks test for comparing between right and left forelimb in each group.
* p 6 0.05.
** p 6 0.001 versus opposite limb of the same group.
Table 2
Neuro-behavior findings in control, 6-OHDA untreated group and preventive group 6 weeks after intrastriatal injection of 6-OHDA.
Controls 6-OHDA untreated group CeO2NPs –preventive group KWv2 p
Latency to move in second 4.0(2–6) 70.50(45.8–84.3)$$ 31.0(22.3–43.5)$$,# 23.906* <0.001*
Squares crossed 24.0(19–28.8) 8.0(4–9.3)$$ 17.0(10.8–20.3)$,# 18.951* <0.001*
Latency to rear in second 12.50(7–19.5) 36.0(18.3–45.5)$ 21.50(19.3–26.8)$ 8.115* 0.017*
No of rear 13.0(7.8–15.5) 3.50(2–4.3)$$ 5.50(3.8–9)$ 17.722* <0.001*
Rotarod test F P
Mean time of latency to falla 101.10 ± 21.44 30.27$$ ± 8.02 50.07$$,# ± 7.30 69.431* <0.001*
Stepping test KWv2 p
Mean Total Steps have taken by RT forelimbb 22.0(19.8–34.5) 1.0(0.0–2)$$ 7.0(6.5–8.3)$$,## 25.980* <0.001*
Mean Total Steps have taken by LT forelimbb 25.50(21.5–37) 28.50(11.8–30.5) 26.0(17–27.8) 0.713 0.700
WRSTp 0.118 0.005* 0.005*
Data were expressed as medians (inter-quartile range) and analyzed by non–parametric ANOVA (Kruskal Wallis), followed when significant by MannWhitney test, except for
mean time of latency to fall in rotarod test, where data were expressed as Mean ± SD and analyzed by (one way ANOVA), followed by Post-Hoc Tukey test. Each group
contained 10 rats.
** p 6 0.001 versus opposite limb of the same group.
a Data represented mean of three trials for each rat.
b Data were expressed as the sum of forehand and backhand steps made by each forepaw.
$ P 6 0.05,
$$ P 6 0.001 versus control group,
# P 6 0.05,
## P 6 0.001 versus 6-OHDAgroup. Wilcoxon signed ranks test for comparing between right and left forelimb in each group.
* p 6 0.05,
Table 3
Neuro-behavior findings in the preventive group 3 and 6 weeks after intrastriatal injection of 6-OHDA.
After 3 weeks (n = 10) After 6 weeks (n = 10) Test of Sig. p
Latency to move (seconds) 31.50 (23.0–45.0) 31.0 (20.0–50.0) Z = 0.877 0.380
Number of crossed Squares 17.50 (11.0–23.0) 17.0 (5.0–22.0) Z = 0.842 0.400
Latency to rear in (seconds) 11.50 (4.0–32.0) 21.50 (17.0–33.0) Z = 2.536* 0.011*
Number of rears 8.0 (4.0–11.0) 5.50 (0.0–10.0) Z = 1.196 0.232
Mean time of latency to fall 52.97 ± 1.87 50.07 ± 2.31 t = 3.728* 0.005*
Total Steps taken by RT forelimb 7.0 (4.0–11.0) 7.0 (4.0–10.0) Z = 0.272 0.785
Total Steps taken by LT forelimb 19.50 (14.0–24.0) 26.0 (20.0–44.0) Z = 2.366* 0.018*
Time to initiate steps by RT forelimb 16.17 (15.0–20.0) 22.33 (15.67–30.0) Z = 2.805* 0.005*
Time to initiate steps by LT forelimb 6.67 (3.90–8.33) 5.67 (4.33–7.67) Z = 1.073 0.283
t: Paired t-test
Z: Z for Wilcoxon signed ranks test
* Statistically significant at p 6 0.05
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Fig. 1. Open field parameters: (A) latency to move (seconds), (B) number of crossed squares (C) latency to rear and (D) number of rears, three weeks following intrastriatal
injection 6-OHDA injection. Data are expressed as medians (intra-quartile rang), $ P 6 0.05, $$ P 6 0.001versus control group, # P 6 0.05, ## P 6 0.001 versus 6-OHDAgroup.
Fig. 2. Comparison between the different groups according to Dopamine HPLC
(ng/mg tissue).
Fig. 3. Comparison between the different groups according to TAC (mM/mg
protein).
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oxidative stress. Low dose administration of CeO2NPs in the pre-
ventive group succeeded in ameliorating this oxidative stress
where a significant difference was observed between preventive
group and untreated group in comparing MDA and TAC levels
but not for nitrite level. Although this low dose of CeO2NPs failed
to return the oxidative stress markers back to normal (see Fig. 6).
3.2.3. Striatal caspase-3 activity
The present study showed that there was a significant increase
in striatal caspase-3 activity in 6-OHDA untreated group versuscontrol rats. The low dose of CeO2NPs decreased striatal caspase-
3 activity as compared to 6-OHDA untreated group and returned
back to levels comparable with the control group.
3.3. Correlation analysis
3.3.1. Correlation between neurobehavioral findings and biochemical
markers in all studied groups
The levels of dopamine and TAC showed significant negative
correlations with the time of latency to move and significant
Fig. 4. Comparison between the different groups according to MDA (nM/g tissue).
Fig. 5. Comparison between the different groups according to Nitrite (lM/mg
protein).
Fig. 6. Comparison between the different studied groups according to ratio of
CASPASE 3 activity.
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ber of rears. On the other hand, MDA, nitrite and caspase 3 activity
were positively correlated with the time of latency to start moving
and rearing and negatively correlated with number of rears and
crossed squares. The Mean time of latency to fall was positively
correlated with dopamine and TAC but negatively correlated with
MDA, nitrite and caspase 3 activity.
The total number of steps taken by RT forelimb showed signif-
icant positive correlations with dopamine and TAC levels and sig-
nificant negative correlations with MDA, nitrite and caspase 3
activity while the time to initiate stepping was positively
correlated with MDA, nitrite and caspase 3 activity and negativelycorrelated with dopamine and TAC. However, correlation between
biochemical markers and left forelimb results were insignificant
(Table 4).3.3.2. Correlations between neurobiochemical findings in all studied
groups: (Fig. 7)
A significant positive correlations was observed between dopa-
mine and TAC (r = 0.742⁄⁄ & p = <0.001) whereas a negative corre-
lation was noticed between dopamine and MDA(r = 0.659⁄⁄ &
p = <0.001), nitrite (r = 544⁄⁄ & p = 0.002⁄⁄) as well as caspase 3
(r = 0.626⁄⁄ & p = <0.001).
In addition, TAC was negatively correlated with MDA, nitrie and
caspase 3 activity where r = 0.779, 0.578⁄⁄, 0.822 respectively
and P = <0.001 for all. As regard MDA, it showed a significant pos-
itive correlations with nitrite (r = 00.639⁄⁄ & p = <0.001) and cas-
pase 3 activity (r = 0.553⁄⁄ & p = 0.002). Caspase 3 activity also
showed a significant negative correlation with TAC (r = 0.822 &
P = <0.001) and a significant positive correlation with MDA
(r = 0.553 & P = 0.002) and nitrite (r = 0.442 & P = 0.014)4. Discussion
In the current study, compared to control rats, 6-OHDA injected
group showed manifestations of PD as demonstrated by a signifi-
cant impairment of motor skills. There was reduction in the num-
ber of rears and squares crossed, and increase in latency to start
moving and rearing suggesting bradykinesia. This was in agree-
ment with Rizelio et al.35 who found impaired motor activity in
6-OHDA rat model. It has been reported that 6-OHDA lesion
induced bradykinesia with the contralateral forelimb.36 In our
study, right side affection was detected in rats injected with 6-
OHDA in the left striatum compared with control rats or the left
forelimb of the same rat which is consistent with previous stud-
ies.37,38 This may be explained by striato-cortical connections
directly or indirectly through the thalamus (indirect and direct
pathway).39 Moreover, 6-OHDA injected rats also exhibited incoor-
dination and loss of stability as shown by reduction in the mean
latency to fall as compared with control rats. This finding is sup-
ported by the study of Iancu et al.37 who found that the time spent
in rotating rod was inversely correlated with cell loss.
The exact pathogenic mechanism for neurodegeneration in PD
is not fully understood. Oxidative stress in brain is an important
factor in the neuropathology of PD.40 In the present study, the cen-
tral administration of 6-OHDA leads to cellular oxidative stress as
demonstrated by the significant reduction of TAC level when com-
pared to controls. This is in agreement with the study by Lefter
et al.41 who found that 6-OHDA lesion resulted in significant
depression in total antioxidant activity and increased oxidative
stress levels in rats’ brains. The present study also showed a signif-
icant elevation in striatal MDA level in 6-OHDA injected rats com-
pared to controls which is in parallel with previous studies.42,43
The nitrite level was also significantly higher in 6-OHDA injected
rats compared to controls. This is consistent with the study of
Guo et al.44 who found that ROS-NO pathway was strongly
involved in the toxicity of 6-OHDA-induced nigrostriatal lesions.
The dopamine depletion noted in our study in 6-OHDA
untreated rats can be explained by the associated oxidative stress
state observed in these rats. Previous studies have shown that 6-
OHDA is transported into dopaminergic neurons where it is oxi-
dized to produce hydrogen peroxide, superoxide, and hydroxyl
radicals and resulted in potent inhibition of the mitochondrial res-
piratory chain complexes I and IV with subsequent depletion of
dopamine level.45,46 It is known that oxidative stress plays an
important role in the degeneration of dopaminergic neurons and
dopamine depletion in Parkinson’s disease.47 This explanation
Table 4
Correlation between neurobehavioral findings and biochemical markers in all studied rats.
Dopamine TAC MDA Nitrite Caspase 3
Latency to move (s) r1 0.741** 0.774** 0.720** 0.497** 0.734**
P <0.001** <0.001** <0.001** 0.005** <0.001**
Number of crossed Squares r1 0.663** 0.708** 0.724** 0.470** 0.613**
P <0.001** <0.001** <0.001** 0.009** <0.001**
Latency to rear in (s) r1 0.289 0.487** 0.506** 0.546** 0.367*
P 0.121 0.006** 0.004** 0.002** 0.046*
Number of rears r1 0.633** 0.731** 0.544** 0.565** 0.654**
P <0.001** <0.001** 0.002** 0.001** <0.001**
Mean time of latency to fall r2 0.827** 0.822** 0.670** 0.456* 0.767**
P <0.001** <0.001** <0.001** <0.001** <0.001**
Total Steps taken by RT forelimb r1 0.720** 0.905** 0.723** 0.542** 0.819**
P <0.001** <0.001** <0.001** 0.002** <0.001**
Total Steps taken by LT forelimb r1 0.122 0.284 0.036 0.081 0.035
P 0.521 0.128 0.852 0.670 0.856
Time to initiate steps by RT forelimb r1 0.804** 0.840** 0.810** 0.533* 0.682**
P <0.001** <0.001** <0.001** <0.001** <0.001**
Time to initiate steps by LT forelimb r1 0.138 0.065 0.276 0.038 0.145
P 0.467 0.733 0.141 0.840 0.446
r1: Spearman coefficient correlation, r2: Pearson coefficient,
* p 6 0.05.
** p 6 0.01. spearman coefficient correlation between neurobiochemical markers and neurobehavioral findings in all studied groups (n = 60) except the mean time of
latency to fall with biochemical markers assessed by pearson correlation in all studied groups (n = 60).
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Fig. 7. Correlations between dopamine levels, oxidative stress markers (TAC, MDA & Nitrite) and caspase 3 measured in striatal tissue of all studied groups.
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relation was detected between striatal dopamine and TAC levels
as well as the significant negative correlation between dopamine,MDA and nitrites levels. These findings were in agreement with
Nagatsu et al.48 who reported a role of oxidative stress in dopamine
depletion.
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mechanisms leading to neurodegeneration in PD49 The present
study showed a significant elevation of brain caspase 3 activity
ratio in 6-OHDA rats compared to control rats. Several studies have
pinpointed a role for the mitochondrial-caspase cascade in 6-
OHDA-induced apoptosis, which initiates the activation of the
main effector caspase- 3.50–52 It is reported that 6-OHDA initiates
cellular oxidative stress, enters neurons via DAT and initiates the
activation of cell death pathways by generation of intracellular free
radicals and mitochondrial inhibition.11 In addition. The current
study revealed a significant negative correlation between striatal
levels of caspase 3 and dopamine as well as TAC, whereas a positive
relationship between caspase 3, MDA and nitrite was noticed.
These findings supported the fact that caspase 3 plays an impor-
tant role as a mediator of cell death in PD.
The correlation between oxidative stress markers and motor
performance in this study was also verified from the positive cor-
relation found between striatal MDA, nitrite and caspase 3 with
latency to start movement (latency to move, latency to rear, time
taken to initiate steps by RT and LT forelimb). Moreover, a negative
correlation was detected with motor activities (number of crossed
squares, number of rears and total steps taken by RT and LT
forelimb). Therefore, it could be suggested that 6-OHDA induced
oxidative stress and neuronal cell apoptosis with subsequent
neurological motor deficits.
Cerium oxide nanoparticles, one of the most interesting nano-
materials for their catalytic properties, show a promise for applica-
tion in medicine. Due to the presence of oxygen on its surface and
autoregenerative cycle of its two oxidation states, Ce3+ and Ce4+,
CeO2NPs can be used as an antioxidant agent. Thus, cerium oxide
nanoparticles may be used as a tool for the treatment of many dis-
orders which are associated with oxidative stress and apoptosis.53
The use of low dose of CeO2NPs in the current study as a neuro-
protective agent in 6-OHDA- injected group was variably effective
in improving the motor functions and ameliorating the changes
that accompanied PD. CeO2NPs succeeded in providing some pro-
tection against the impairment of locomotor behavior after three
weeks although theses dose failed to preserve the motor functions
as in normal rats. After six weeks CeO2-NPs failed to produce the
same protective effect and showed only partial improvement in
some open field parameters (numbers of squares crossed, and
latency to move only). Regarding the motor performance in rotarod
test; there was also a significant improvement of latency scores
after three and six weeks from the use of low doses of CeO2NPs
treatments compared to 6-OHDA untreated rats, although it was
less effective after six weeks. In addition, this study showed slight
improvement in initiation time and number of steps taken by right
forelimb in the preventive group after three and six weeks but it
also produced less improvement after six weeks.
This partial improvement in motor performance and coordina-
tion in neurobehavioral results was also reported by Heckman
et al.54 who found that CeO2NPs improved motor functions in
autoimmune neurodegenerative disease. In addition, several
studies approved neuroprotective effects of CeO2NPs on motor
dysfunction.55,56 Thus, CeO2NPs preserved motor performance in
6-OHDA- injected group but they failed to preserve almost motor
performance scores as control level. They also failed to produce
the same protective effect with persistent neurodegeration for long
period as it was observed in our study after six weeks. This may be
attributed to the low dose used in this study which was insufficient
to prevent the marked neurodegeneration and produce valuable
neuroprotection especially for long period.
This neuroprotective effect of CeO2NPs has been attributed to
different mechanisms. Enhancement of antioxidant capacity, pre-
vention of reactive oxygen species (ROS) generation and attenua-
tion of apoptosis are important mechanisms carried by CeO2 NPswith subsequent restoration of striatal dopamine levels.57,14 Our
results provide some support to these mechanisms as treatment
of 6-OHDA injected rats with low dose of CeO2 NPs caused eleva-
tion in striatal TAC levels compared 6-OHDA untreated group. This
was in agreement with the study of Yu et al.58 and Hochella et al.59
who found that the antioxidative effect of CeO2 nanoparticles is
attributed to its direct exchange between ROS and the high ratio
of electrons on the larger surface area of the nanoparticles.
CeO2 NPs treatment also caused significant reduction in striatal
MDA level compared to 6-OHDA untreated group. As previously
observed, CeO2NPs, can scavenge almost all types of reactive spe-
cies, has excellent regeneration ability and can cross the blood
brain barrier (BBB) because of its nano size.60
Dowding and co-workers61 explored and demonstrated the NO
scavenging ability of CeO2NP. The possible mechanism by which
CeO2NPs scavenges NO is through formation of an electropositive
nitrosyl ligand caused by internal electron transfer from NO to a
Ce4.62 This was contrary to our results where the low dose of
CeO2NPs failed to produce such effect.
Several studies reported the potential therapeutic benefits of
CeO2NPs in many diseases where they have been shown to scav-
enge ROS and provide neuroprotection.15–17 Because of its multiple
antioxidant-enzyme-like activities, including SOD, catalase,
peroxidase-like activities, and hydroxyl radical and nitric oxide
radical scavenging properties, CeO2NPs was expected to scavenge
almost all types of reactive species. This makes it superior to any
antioxidant enzyme or molecule because they often scavenge only
a single type of free radical before being inactivated.16
In the present study, CeO2NPs caused a significant reduction in
caspase-3 when compared to 6-OHDA untreated group. It is
thought that CeO2 NPs protect cells and tissues from damage by
its regenerative free radical scavenging property. This was in accor-
dance with study of Colon et al.63 who investigated the protective
effect of CeO2NPs against radiation induced damage. Estevez and
coworkers64 reported that CeO2 could reduce ischemic cell death
in mice hippocampal brain slices by 50%.
Although the low dose of CeO2NPs succeeded in improving the
oxidative stress and cell death partially but they were unable to
regain it back to normal condition. Moreover, this low dose of
CeO2NPs failed to reduce nitrite level. Thus, this low dose of CeO2-
NPs was not able to cause complete amelioration of the profound
oxidative stress state which was produced by 6-OHDA. This could
explain the inability of such dose of CeO2NPs to provide complete
protection of dopaminergic neurons and to preserve dopamine
within normal levels. The Negative correlation observed between
dopamine and nitrite as well as MDA provided more support to
this explanation. The low dose of CeO2NPs showed improvements
in only some biochemical aspects which led to improvement in
some motor performances.
The use of such low dose in the current work was based on the
results of many previous studies which revealed that extensive
application of CeO2 nanoparticles may induce oxidative stress,
apoptosis and cytotoxicity.65–67 Dillon et al.68 reported that once
the dose achieved a certain maximum level of benefit, neuropro-
tective effect declined. Kim et al.55 also found that the indiscrimi-
nate use of nanoparticles without considering the optimal dose
may not be protective and may even be harmful.
In conclusion, the use of low dose of CeO2NPs showed partial
protection against the neurochemical disturbances and motor dis-
turbances in 6-OHDA induced parkinsonian rat model. CeO2NPs
represent a novel neuroprotective agent in PD and they can
improve motor performance through their antioxidant and anti
apoptotic effects. Further studies are needed to examine the
neuroprotective effect of higher doses of CeO2NPs and protection
against the development of behavioral and biochemical changes
in Parkinson’s disease.
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